Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Shares Outstanding (Diluted Average) (2021 - 2025)

Immunocore Holdings' Shares Outstanding (Diluted Average) history spans 3 years, with the latest figure at $50.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 0.71% year-over-year to $50.3 million; the TTM value through Dec 2025 reached $50.3 million, up 0.71%, while the annual FY2025 figure was $50.3 million, 0.71% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $50.3 million at Immunocore Holdings, roughly flat from $50.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $54.2 million in Q3 2023 and bottomed at $48.2 million in Q1 2023.
  • The 3-year median for Shares Outstanding (Diluted Average) is $50.1 million (2024), against an average of $50.5 million.
  • The largest YoY upside for Shares Outstanding (Diluted Average) was 4.16% in 2025 against a maximum downside of 4.55% in 2025.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $48.9 million in 2023, then grew by 2.25% to $50.0 million in 2024, then increased by 0.71% to $50.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Shares Outstanding (Diluted Average) are $50.3 million (Q4 2025), $50.4 million (Q3 2025), and $50.3 million (Q2 2025).